Description

Racemic-(4As,6S,7As)-4-tert-Butyl 6-Ethyl Hexahydrocyclopenta[B][1,4]Oxazine-4,6(4Ah)-Dicarboxylate (Wx110663) is a high-purity, advanced pharmaceutical intermediate characterized by its complex, stereochemically defined oxazine-bicyclic structure. This compound is of significant value in the synthesis of novel active pharmaceutical ingredients (APIs), particularly those targeting central nervous system (CNS) disorders and other therapeutic areas requiring sophisticated molecular architectures. It is primarily sought by research institutions, contract development and manufacturing organizations (CDMOs), and pharmaceutical companies engaged in process development and scale-up for new chemical entities.

Application

• Pharmaceutical Intermediate: A key chiral building block in the research and commercial synthesis of proprietary drug candidates.
• Process Chemistry & Scale-Up: Used in route scouting, optimization, and pilot-scale production for new molecular entities under GMP conditions.
• Medicinal Chemistry Research: Serves as a versatile scaffold for generating compound libraries in drug discovery programs, especially for CNS targets.
• Asymmetric Synthesis: Utilized in the development of stereoselective catalytic processes due to its defined stereocenters.
• Reference Standard: Provides a high-purity standard for analytical method development, validation, and quality control in API manufacturing.

Basic Information

Product Name	Racemic-(4As,6S,7As)-4-tert-Butyl 6-Ethyl Hexahydrocyclopenta[B][1,4]Oxazine-4,6(4Ah)-Dicarboxylate (Wx110663)
CAS No.	1290625-35-2
Molecular Formula	C17H27NO5
Molecular Weight	325.40 g/mol
Synonyms	4-tert-Butyl 6-ethyl hexahydrocyclopenta[b][1,4]oxazine-4,6(4aH)-dicarboxylate; (±)-(4aR,6S,7aR)-4-(tert-Butoxycarbonyl)-6-ethoxycarbonyl-4,4a,5,6,7,7a-hexahydrocyclopenta[b][1,4]oxazine; WX-110663; Wx110663; Hexahydrocyclopenta[b][1,4]oxazine-4,6(4aH)-dicarboxylic acid, 4-(1,1-dimethylethyl) 6-ethyl ester, (4aR,6S,7aR)-rel-; Bicyclic oxazine ester intermediate; tert-Butyl ethyl hexahydrocyclopentaoxazinedicarboxylate.
EINECS	Contact for details

Quality Control

Our Racemic-(4As,6S,7As)-4-tert-Butyl 6-Ethyl Hexahydrocyclopenta[B][1,4]Oxazine-4,6(4Ah)-Dicarboxylate is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including chiral HPLC, NMR, and mass spectrometry, to ensure identity, purity, and stereochemical integrity. We provide full traceability and detailed Certificates of Analysis (COA) with every shipment, supporting development under ICH Q7 guidelines and cGMP standards for pharmaceutical intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (15-25°C). The compound may be hygroscopic; keep the container tightly sealed under an inert atmosphere if necessary for long-term storage.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Chiral Purity (Chiral HPLC)	≥ 99.0% (Racemic mixture)
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.